Cell Signaling Technology

Product Pathways - DNA Damage

Phospho-p53 Antibody Sampler Kit #9919

Kit Includes Quantity Applications Reactivity MW (kDa) Isotype
Phospho-p53 (Ser6) Antibody #9285 40 µl W IP IC H Mk (Hm) 53 Rabbit
Phospho-p53 (Ser9) Antibody #9288 40 µl W IP H Mk 53 Rabbit
Phospho-p53 (Ser15) Antibody #9284 40 µl W IP IF-IC ChIP H M R Mk 53 Rabbit
p53 (7F5) Rabbit mAb #2527 40 µl W IHC-P IF-IC F ChIP H Mk 53 Rabbit IgG
Phospho-p53 (Ser20) Antibody #9287 40 µl W H Mk 53 Rabbit
Phospho-p53 (Ser37) Antibody #9289 40 µl W IF-IC F H Mk 53 Rabbit
Phospho-p53 (Ser46) Antibody #2521 40 µl W IP IF-IC F H Mk 53 Rabbit
Phospho-p53 (Ser392) Antibody #9281 40 µl W H M 53 Rabbit
Phospho-p53 (Thr81) Antibody #2676 40 µl W IHC-P IF-IC H Mk 53 Rabbit
Anti-rabbit IgG, HRP-linked Antibody #7074 100 µl Goat

Applications Key:  W=Western Blotting  IP=Immunoprecipitation  IHC-P=Immunohistochemistry (Paraffin)  IF-IC=Immunofluorescence (Immunocytochemistry)  IC=Immunocytochemistry  F=Flow Cytometry  ChIP=Chromatin IP
Reactivity Key:  H=Human  M=Mouse  R=Rat  Hm=Hamster  Mk=Monkey
Species enclosed in parentheses are predicted to react based on 100% sequence homology.

Specificity / Sensitivity

Phospho-p53 (Ser6), (Ser9), (Ser15), (Ser20), (Ser37), (Thr81), and (Ser392) Antibodies detect p53 only when phosphorylated at the indicated sites and do not cross-react with p53 phosphorylated at other sites.

Western Blotting

Western Blotting

Western blot analysis of extracts from 293 and COS cells, using p53 (7F5) Rabbit mAb #2527.

Western Blotting

Western Blotting

Western blot analysis of extracts from HT29 cells, untreated, nocodazole-treated (50 ng/ml, 24h) or UV-treated (50mJ/cm2, 1hr), using Phospho-p53 (Thr81) Antibody #2676 (upper), p53 (1C12) Mouse mAb #2524 (middle), or Phospho-SAPK/JNK(T183/Y185) (98F2) Rabbit mAb #4671 (lower).

Western Blotting

Western Blotting

Western blot analysis of extracts from hydroxyurea (20 mM) treated MvILu cells, using Phospho-p53 (Ser392) Antibody #9281.


Western Blotting

Western Blotting

Western blot analysis of extracts from UV or hydroxyurea (20 mM) treated MvILu cells, using Phospho-p53 (Ser15) Antibody #9284.

Western Blotting

Western Blotting

Specificity and sensitivity of Phospho-p53 (Ser15) Antibody #9284. Western blot analysis of p53 fusion protein with and without DNA-PK phosphorylation, using Phospho-p53 (Ser15) Antibody (upper) and p53 Antibody #9282 (lower).

Western Blotting

Western Blotting

Western blot analysis of extracts from UV treated PC12 cells or HeLa cells, using Phospho-p53 (Ser15) Antibody #9284.


Western Blotting

Western Blotting

Western blot analysis of extracts from COS cells treated with UV or MMS, using Phospho-p53 (Ser6) Antibody #9285 or p53 Antibody #9282.

Western Blotting

Western Blotting

Western blot analysis of p53 fusion protein with and without CKI or CKII phosphorylation, using Phospho-p53 (Ser6) Antibody #9285 or p53 Antibody #9282.

Description

The Phospho-p53 Antibody Sampler Kit provides a fast and economical means of evaluating multiple phosphorylation sites of p53 protein. The kit contains enough primary and secondary antibodies to perform four Western blot experiments.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with synthetic phosphopeptides corresponding to residues surrounding Ser6, Ser9, Ser15, Ser20, Ser37, Thr81, and Ser392 of human p53. Polyclonal antibodies are purified by protein A and peptide affinity chromatography. Monoclonal antibody is produced by immunizing animals with a MBP-p53 fusion protein.

Background

The p53 tumor suppressor protein plays a major role in cellular response to DNA damage and other genomic aberrations. Activation of p53 can lead to either cell cycle arrest and DNA repair or apoptosis (1). p53 is phosphorylated at multiple sites in vivo and by several different protein kinases in vitro (2,3). DNA damage induces phosphorylation of p53 at Ser15 and Ser20 and leads to a reduced interaction between p53 and its negative regulator, the oncoprotein MDM2 (4). MDM2 inhibits p53 accumulation by targeting it for ubiquitination and proteasomal degradation (5,6). p53 can be phosphorylated by ATM, ATR, and DNA-PK at Ser15 and Ser37. Phosphorylation impairs the ability of MDM2 to bind p53, promoting both the accumulation and activation of p53 in response to DNA damage (4,7). Chk2 and Chk1 can phosphorylate p53 at Ser20, enhancing its tetramerization, stability, and activity (8,9). p53 is phosphorylated at Ser392 in vivo (10,11) and by CAK in vitro (11). Phosphorylation of p53 at Ser392 is increased in human tumors (12) and has been reported to influence the growth suppressor function, DNA binding, and transcriptional activation of p53 (10,13,14). p53 is phosphorylated at Ser6 and Ser9 by CK1δ and CK1ε both in vitro and in vivo (13,15). Phosphorylation of p53 at Ser46 regulates the ability of p53 to induce apoptosis (16). Acetylation of p53 is mediated by p300 and CBP acetyltransferases. Inhibition of deacetylation suppressing MDM2 from recruiting HDAC1 complex by p19 (ARF) stabilizes p53. Acetylation appears to play a positive role in the accumulation of p53 protein in stress response (17). Following DNA damage, human p53 becomes acetylated at Lys382 (Lys379 in mouse) in vivo to enhance p53-DNA binding (18). Deacetylation of p53 occurs through interaction with the SIRT1 protein, a deacetylase that may be involved in cellular aging and the DNA damage response (19).

  1. Levine, A.J. (1997) Cell 88, 323-331.
  2. Meek, D.W. (1994) Semin. Cancer Biol. 5, 203-210.
  3. Milczarek, G.J. et al. (1997) Life Sci. 60, 1-11.
  4. Shieh, S.Y. et al. (1997) Cell 91, 325-334.
  5. Chehab, N.H. et al. (1999) Proc. Natl. Acad. Sci. USA 96, 13777-13782.
  6. Honda, R. et al. (1997) FEBS Lett. 420, 25-27.
  7. Tibbetts, R.S. et al. (1999) Genes Dev. 13, 152-157.
  8. Shieh, S.Y. et al. (1999) EMBO J. 18, 1815-1823.
  9. Hirao, A. et al. (2000) Science 287, 1824-1827.
  10. Hao, M. et al. (1996) J. Biol. Chem. 271, 29380-29385.
  11. Lu, H. et al. (1997) Mol. Cell. Biol. 17, 5923-5934.
  12. Ullrich, S.J. et al. (1993) Proc. Natl. Acad. Sci. USA 90, 5954-5958.
  13. Kohn, K.W. (1999) Mol. Biol. Cell 10, 2703-2734.
  14. Lohrum, M. and Scheidtmann, K.H. (1996) Oncogene 13, 2527-2539.
  15. Knippschild, U. et al. (1997) Oncogene 15, 1727-1736.
  16. Oda, K. et al. (2000) Cell 102, 849-862.
  17. Ito, A. et al. (2001) EMBO J. 20, 1331-1340.
  18. Sakaguchi, K. et al. (1998) Genes Dev. 12, 2831-2841.
  19. Solomon, J.M. et al. (2006) Mol. Cell. Biol. 26, 28-38.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Protocols

Companion Products


This product is intended for research purposes only. The product is not intended to be used for therapeutic or diagnostic purposes in humans or animals.

Products